Drug Trial Radar · NCT03777059
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Jul 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
910
Actual
Start
Dec 14, 2018
Primary completion
Jun 19, 2020
Study completion Jun 19, 2020
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Conditions
- Episodic Migraine
Interventions
AtogepantDrug
Atogepant tablet
PlaceboDrug
Placebo-matching atogepant tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment PeriodTime frame: Baseline (Day -28 to Day -1) to Week 12
Locations
138 sites in 1 country. Site status is shown where the registry gives one.
Synexus Clinical Research US, Inc.
Chandler, Arizona
Advanced Research Associates
Glendale, Arizona
Alea Research Institute
Phoenix, Arizona
Barrow Neurological Institute
Phoenix, Arizona
Orange Grove Family Practice
Tucson, Arizona
Principals Research Group
Hot Springs, Arkansas
Arkansas Clinical Research
Little Rock, Arkansas
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Med Center Medical Clinic
Carmichael, California
Triwest Research Associates
El Cajon, California
Neuro Pain Medical Center
Fresno, California
California Headache and Balance Center
Fresno, California
Fullerton Neurology and Headache Center
Fullerton, California
Neurology Center of North Orange County
Fullerton, California
NervePro Research Bruce Cleeremans
Irvine, California
Grossmont Center for Clinical Research
La Mesa, California
Torrance Clinical Research Institute, Inc.
Lomita, California
Long Beach Clinical Trials Services
Long Beach, California
Keck Medicine of USC
Los Angeles, California
Pharmacology Research Institute
Newport Beach, California
Newport Beach Clinical Research Associates
Newport Beach, California
Excell Research, Inc.
Oceanside, California
Stanford
Palo Alto, California
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California
Desert Valley Research
Redlands, California
George J. Rederich, M.D. Inc.
Redondo Beach, California
Paradigm Clinical Research Centers, Inc
San Diego, California
Optimus Medical Group
San Francisco, California
California Neuroscience Research
Sherman Oaks, California
Synexus Clinical Research US, Inc.
Vista, California
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Delta Waves, Inc.
Colorado Springs, Colorado
Colorado Neurological Institute
Englewood, Colorado
New England Institute for Clinical Research
Stamford, Connecticut
Aventura Neurological Associates
Aventura, Florida
Neurology Offices of South Florida
Boca Raton, Florida
Sarkis Clinical Trials- Gainesville
Gainesville, Florida
Westside Center for Clinical Research
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Neurology Associates, P.A.
Maitland, Florida
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.